QYUNS-B (official name: Qyuns Therapeutics Co., Ltd.) has published an updated roster of its Board of Directors and detailed the latest composition of its four specialised committees. The disclosure, dated 22 September 2026, outlines the current governance structure following recent adjustments.
\n\nKey Board Appointments\n• Executive Directors: Mr. Qiu Jiwan continues as Chairman and General Manager, joined by Mr. Wu Yiliang and Mr. Lin Weidong.\n• Non-executive Director: Mr. Wu Zhiqiang remains on the Board.\n• Independent Non-executive Directors: Mr. Fung Che Wai, Anthony (designated Lead Independent Director), Dr. Zou Zhongmei and Dr. Ling Jianqun provide external oversight.
\n\nCommittee Structure\n1. Audit Committee – Chaired by Mr. Fung Che Wai, Anthony, with Dr. Zou Zhongmei and Dr. Ling Jianqun serving as members.\n2. Remuneration and Appraisal Committee – Led by Dr. Ling Jianqun; Dr. Zou Zhongmei and Mr. Wu Zhiqiang participate as members.\n3. Nomination Committee – Chaired by Mr. Qiu Jiwan, flanked by Dr. Zou Zhongmei and Dr. Ling Jianqun.\n4. Strategy and Development Committee – Headed by Mr. Qiu Jiwan, with membership comprising Mr. Wu Zhiqiang.
\n\nGovernance Implications\nThe refreshed committee assignments highlight a concentration of strategic leadership under Chairman Qiu Jiwan, who presides over both the Nomination and Strategy & Development Committees. Independent oversight is reinforced through Mr. Fung’s leadership of the Audit Committee and Dr. Ling’s role heading Remuneration and Appraisal.
\n\nEffective Date\nAll appointments and committee memberships are effective as stated in the announcement released on 22 September 2026 in Hong Kong.
Comments